Skip to main content
ICYMI Multiple Sclerosis
FULL MENU
FULL MENU
Presented by
MDedge Neurology
Clinical Topics
Conference Coverage
Literature Review
MD-IQ
Clinical Edge Journal Scan
Audio
Mark Freedman, MD
Publish date:
July 24, 2013
The Promise of Mesenchymal Stem Cells for Patients With MS
Recommended Reading
New and Noteworthy Information—May 2013
ICYMI Multiple Sclerosis
PEGylated Interferon Beta-1a May Reduce Annualized Relapse Rate in Patients With MS
ICYMI Multiple Sclerosis
Stuart Cook, MD, Discusses the CMSC Joint Statement on Adding MRI to the Lublin–Reingold Classification of MS
ICYMI Multiple Sclerosis
Could Stem Cells Reduce Inflammatory Lesions in Patients With MS?
ICYMI Multiple Sclerosis
How Prevalent Is Pain in MS?
ICYMI Multiple Sclerosis
Tool May Identify Risk of Transition to Secondary Progressive MS
ICYMI Multiple Sclerosis
News Briefs From the Fifth Cooperative Meeting of CMSC/ACTRIMS
ICYMI Multiple Sclerosis
Anti-JCV Antibody Index May Further Define PML Risk
ICYMI Multiple Sclerosis
Fingolimod Slows MS Brain Atrophy Within Six Months
ICYMI Multiple Sclerosis
Simvastatin May Reduce Brain Atrophy in Patients With Secondary Progressive MS
ICYMI Multiple Sclerosis
Related Articles
Conference Coverage
Could Stem Cells Reduce Inflammatory Lesions in Patients With MS?
Read More
Multiple Sclerosis
FULL MENU
FULL MENU
Presented by
FULL MENU
FULL MENU
Clinical Topics
Conference Coverage
Expert Perspectives
Literature Review
MD-IQ
Clinical Edge Journal Scan
More
MDedge Neurology
Clinical Topics
Conference Coverage
Expert Perspectives
Literature Review
MD-IQ
Clinical Edge Journal Scan
More
MDedge Neurology